|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Trading: NO POSITION @ $0.105
Signal Strength: WEAK
Indicator MUST BE USED in additional to another technical indicator to confirmation for trading entry. Indicator can be applied to the short term timeframe but is only able to give and indication of the strength of the buyers versus sellers at the market close. This bar analysis can provide guidance on the daily battle between sellers and buyers from the companies recent trading.
Impedimed (ASX:IPD) Neither buyers are keener than sellers translating to the price remaining flat for Impedimed. This is the first day of neutral price movement for IPD adding strength to indecision in the first timeframe. The longest consecutive number of unchanged days over the last 12 months has been 5 days, of which a total of 1 have occurred this month. The ratio of neutral days against total trading days equals 0x
The only price most market participants look at is the closing price in relation to the previous day’s close. As such the position of the close has the ability to highlight recent performance and indirectly the keenness of traders.
[Calculations] Close Today Versus Close Yesterday (CTCY):
1) [Close] > [Close Yesterday] = Buyers keener than sellers;
2) [Close] < [Close Yesterday] = Sellers keener than buyers;
3) [Close] = [Close Yesterday] = Neither are keener
PROFILE: Impedimed (IPD.AX)
Stock Exchange: ASX
Ticker Codes: | IPD.AX | ASX:IPD |
ImpediMed Limited, together with its subsidiaries, engages in the development, manufacture, and sale of bioimpedance devices and consumables in Australia, North America, Europe, and internationally. The company operates through Medical and Test & Measurement segments. It offers L-Dex U400, a technology that utilizes the characteristics of frequency dependent current flow to quantify changes in extracellular fluid in the patient's limb; and SFB7, a tetra polar bioimpedance spectroscopy device that scans various frequencies for the estimation of body composition in healthy individuals. The company also provides DF50, a single frequency body composition analysis in healthy individuals; and ImpediVET, a bioimpedance spectroscopy technology for use in veterinary applications. Its products are used in a range of applications, such as in the assessment and monitoring of secondary lymphedema, as well as monitoring of body composition and hydration. In addition, the company is involved in the supply of power precision testing and measuring equipment. ImpediMed Limited was founded in 1999 and is headquartered in Pinkenba, Australia.
|AFL ASX 50||0.16||0||0||0||NEUTRAL|
|AFI Australian Foundation||7.09||0||203,947||0||NEUTRAL|
|AFP Aft Pharmaceuticals||3.1||0||0||0||NEUTRAL|
|AGI Ainsworth Game Technology||0.66||0||56,459||0||NEUTRAL|
|AHY Asaleo Care||1.09||0||100,742||0||NEUTRAL|
|AJM Altura Mining||0.06||0||0||0||NEUTRAL|
|ATM Aneka Tambang||1||0||0||0||NEUTRAL|
|BAF Blue Sky Alternatives||0.89||0||92,565||0||NEUTRAL|
|BFG Bell Financial||1.38||0||161,497||0||NEUTRAL|